Symptomatic Treatment of Extrapyramidal Hyperkinetic Movement Disorders


Citar

Texto integral

Resumo

:Extrapyramidal hyperkinetic movement disorders comprise a broad range of phenotypic phenomena, including chorea, dystonia, and tics. Treatment is generally challenging and individualized, given the overlapping phenomenology, limited evidence regarding efficacy, and concerns regarding the tolerability and safety of most treatments. Over the past decade, the treatment has become even more intricate due to advancements in the field of deep brain stimulation as well as optimized dopamine-depleting agents. Here, we review the current evidence for treatment modalities of extrapyramidal hyperkinetic movement disorders and provide a comprehensive and practical overview to aid the choice of therapy. Mechanism of action and practical intricacies of each treatment modality are discussed, focusing on dosing and adverse effect management. Finally, future therapeutic developments are also discussed.

Sobre autores

Gregory Boer

Department of Neurology and Clinical Neurophysiology,, Amsterdam UMC Location University of Amsterdam

Email: info@benthamscience.net

Robertus Alfonsius de Bie

Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Location University of Amsterdam,

Email: info@benthamscience.net

Bart Sylvain Swinnen

Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Location University of Amsterdam

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Abdo, W.F.; van de Warrenburg, B.P.C.; Burn, D.J.; Quinn, N.P.; Bloem, B.R. The clinical approach to movement disorders. Nat. Rev. Neurol., 2010, 6(1), 29-37. doi: 10.1038/nrneurol.2009.196
  2. Jankovic, J. Treatment of hyperkinetic movement disorders. Lancet Neurol., 2009, 8(9), 844-856. doi: 10.1016/S1474-4422(09)70183-8
  3. André, V.M.; Cepeda, C.; Levine, M.S. Dopamine and glutamate in huntington’s disease: A balancing act. CNS Neurosci. Ther., 2010, 16(3), 163-178. doi: 10.1111/j.1755-5949.2010.00134.x
  4. Frank, S.; Testa, C.M.; Stamler, D.; Kayson, E.; Davis, C.; Edmondson, M.C.; Kinel, S.; Leavitt, B.; Oakes, D.; O’Neill, C.; Vaughan, C.; Goldstein, J.; Herzog, M.; Snively, V.; Whaley, J.; Wong, C.; Suter, G.; Jankovic, J.; Jimenez-Shahed, J.; Hunter, C.; Claassen, D.O.; Roman, O.C.; Sung, V.; Smith, J.; Janicki, S.; Clouse, R.; Saint-Hilaire, M.; Hohler, A.; Turpin, D.; James, R.C.; Rodriguez, R.; Rizer, K.; Anderson, K.E.; Heller, H.; Carlson, A.; Criswell, S.; Racette, B.A.; Revilla, F.J.; Nucifora, F., Jr; Margolis, R.L.; Ong, M.J.; Mendis, T.; Mendis, N.; Singer, C.; Quesada, M.; Paulsen, J.S.; Brashers-Krug, T.; Miller, A.; Kerr, J.; Dubinsky, R.M.; Gray, C.; Factor, S.A.; Sperin, E.; Molho, E.; Eglow, M.; Evans, S.; Kumar, R.; Reeves, C.; Samii, A.; Chouinard, S.; Beland, M.; Scott, B.L.; Hickey, P.T.; Esmail, S.; Fung, W.L.A.; Gibbons, C.; Qi, L.; Colcher, A.; Hackmyer, C.; McGarry, A.; Klos, K.; Gudesblatt, M.; Fafard, L.; Graffitti, L.; Schneider, D.P.; Dhall, R.; Wojcieszek, J.M.; LaFaver, K.; Duker, A.; Neefus, E.; Wilson-Perez, H.; Shprecher, D.; Wall, P.; Blindauer, K.A.; Wheeler, L.; Boyd, J.T.; Houston, E.; Farbman, E.S.; Agarwal, P.; Eberly, S.W.; Watts, A.; Tariot, P.N.; Feigin, A.; Evans, S.; Beck, C.; Orme, C.; Edicola, J.; Christopher, E. Effect of deutetrabenazine on chorea among patients with huntington disease. JAMA, 2016, 316(1), 40-50. doi: 10.1001/jama.2016.8655
  5. Bashir, H.; Jankovic, J. Treatment options for chorea. Expert Rev. Neurother., 2018, 18(1), 51-63. doi: 10.1080/14737175.2018.1403899
  6. Coppen, E.M.; Roos, R.A.C. Current pharmacological approaches to reduce chorea in huntington’s disease. Drugs, 2017, 77(1), 29-46. doi: 10.1007/s40265-016-0670-4
  7. Crosby, N.J.; Deane, K.; Clarke, C.E. Amantadine for dyskinesia in Parkinson’s disease. Cochrane Database of Systematic Reviews; John Wiley and Sons Ltd, 2010.
  8. Reilmann, R. Pharmacological treatment of chorea in Huntington’s disease-good clinical practice versus evidence-based guideline. Mov. Disord., 2013, 28(8), 1030-1033. doi: 10.1002/mds.25500
  9. Smith, K.M.; Spindler, M.A. Uncommon applications of deep brain stimulation in hyperkinetic movement disorders. Tremor Other Hyperkinet. Mov. , 2015, 5, 278. doi: 10.5334/tohm.265
  10. Posturna, R.B.; Lang, A.E. Hemiballism: Revisiting a classic disorder. Lancet Neurol., 2003, 2(11), 661-668. doi: 10.1016/S1474-4422(03)00554-4
  11. Whittier, J.R. Ballism and the subthalamic nucleus (Nucleus Hypothalamicus; Corpus Luysi). Arch. Neurol. Psychiatry, 1947, 58(6), 672-692. doi: 10.1001/archneurpsyc.1947.02300350022002
  12. Mehanna, R.; Jankovic, J. Movement disorders in cerebrovascular disease. Lancet Neurol., 2013, 12(6), 597-608. doi: 10.1016/S1474-4422(13)70057-7
  13. Ganapa, S.V.; Ramani, M.D.; Ebunlomo, O.O.; Rahman, R.K.; Herschman, Y.; Mammis, A. Treatment of persistent hemiballism with deep brain stimulation of the globus pallidus internus: Case report and literature review. World Neurosurg., 2019, 132, 368-370. doi: 10.1016/j.wneu.2019.08.247
  14. Albanese, A.; Bhatia, K.; Bressman, S.B.; DeLong, M.R.; Fahn, S.; Fung, V.S.C.; Hallett, M.; Jankovic, J.; Jinnah, H.A.; Klein, C.; Lang, A.E.; Mink, J.W.; Teller, J.K. Phenomenology and classification of dystonia: A consensus update. Mov. Disord., 2013, 28(7), 863-873. doi: 10.1002/mds.25475
  15. Balint, B.; Mencacci, N.E.; Valente, E.M.; Pisani, A.; Rothwell, J.; Jankovic, J.; Vidailhet, M.; Bhatia, K.P. Author correction. Dystonia. Nat. Rev. Dis. Primers, 2018, 4(1), 37. doi: 10.1038/s41572-018-0039-y
  16. Jankovic, J. Botulinum toxin: State of the art. Mov. Disord., 2017, 32(8), 1131-1138. doi: 10.1002/mds.27072
  17. Termsarasab, P.; Thammongkolchai, T.; Frucht, S.J. Medical treatment of dystonia. J. Clin. Mov. Disord., 2016, 3, 19. doi: 10.1186/s40734-016-0047-6 PMID: 28031858
  18. Cloud, L.J.; Jinnah, H.A. Treatment strategies for dystonia. Expert Opin. Pharmacother., 2010, 11(1), 5-15. doi: 10.1517/14656560903426171 PMID: 20001425
  19. Reese, R.; Volkmann, J. Deep brain stimulation for the dystonias: Evidence, knowledge gaps, and practical considerations. Mov. Disord. Clin. Pract., 2017, 4(4), 486-494. doi: 10.1002/mdc3.12519
  20. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders; American Psychiatric Association, 2013.
  21. Johnson, K.A.; Worbe, Y.; Foote, K.D.; Butson, C.R.; Gunduz, A.; Okun, M.S. Tourette syndrome: Clinical features, pathophysiology, and treatment. Lancet Neurol., 2022, 4422(22), 1-12.
  22. Martino, D.; Hedderly, T. Tics and stereotypies: A comparative clinical review. Parkinsonism Relat. Disord., 2019, 59, 117-124. doi: 10.1016/j.parkreldis.2019.02.005
  23. Martino, D.; Mink, J.W. Tic disorders. Continuum , 2013, 19(5), 1287-1311. doi: 10.1212/01.CON.0000436157.31662.af
  24. Cothros, N.; Medina, A.; Pringsheim, T. Current pharmacotherapy for tic disorders. Expert Opin. Pharmacother., 2020, 21(5), 567-580. doi: 10.1080/14656566.2020.1721465
  25. Pringsheim, T.; Okun, M.S.; Müller-Vahl, K.; Martino, D.; Jankovic, J.; Cavanna, A.E.; Woods, D.W.; Robinson, M.; Jarvie, E.; Roessner, V.; Oskoui, M.; Holler-Managan, Y.; Piacentini, J. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 2019, 92(19), 896-906. doi: 10.1212/WNL.0000000000007466
  26. Roessner, V.; Eichele, H.; Stern, J.S.; Skov, L.; Rizzo, R.; Debes, N.M.; Nagy, P.; Cavanna, A.E.; Termine, C.; Ganos, C.; Münchau, A.; Szejko, N.; Cath, D.; Müller-Vahl, K.R.; Verdellen, C.; Hartmann, A.; Rothenberger, A.; Hoekstra, P.J.; Plessen, K.J. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: Pharmacological treatment. Eur. Child Adolesc. Psychiatry, 2022, 31(3), 425-441. doi: 10.1007/s00787-021-01899-z
  27. Mogwitz, S.; Buse, J.; Wolff, N.; Roessner, V. Update on the pharmacological treatment of tics with dopamine-modulating agents. ACS Chem. Neurosci., 2018, 9(4), 651-672. doi: 10.1021/acschemneuro.7b00460
  28. Behling, E.; Farhat, L.C.; Landeros-Weisenberger, A.; Bloch, M.H. META‐ANALYSIS: Efficacy and tolerability of vesicular monoamine transporter type 2 inhibitors in the treatment of tic disorders. Mov. Disord., 2022, 37(4), 684-693. doi: 10.1002/mds.28957
  29. Chen, J.J.; Ondo, W.G.; Dashtipour, K.; Swope, D.M. Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clin. Ther., 2012, 34(7), 1487-1504. doi: 10.1016/j.clinthera.2012.06.010
  30. Billnitzer, A.; Jankovic, J. Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics. Springer Science and Business Media Deutschland GmbH, 2020, 17, 1681-1693.
  31. Roessner, V.; Eichele, H.; Stern, J.S.; Skov, L.; Rizzo, R.; Debes, N.M. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment.European Child and Adolescent Psychiatry. Springer Science and Business Media Deutschland GmbH, 2022, 31, 425-441.
  32. Martinez-Ramirez, D.; Jimenez-Shahed, J.; Leckman, J.F.; Porta, M.; Servello, D.; Meng, F.G.; Kuhn, J.; Huys, D.; Baldermann, J.C.; Foltynie, T.; Hariz, M.I.; Joyce, E.M.; Zrinzo, L.; Kefalopoulou, Z.; Silburn, P.; Coyne, T.; Mogilner, A.Y.; Pourfar, M.H.; Khandhar, S.M.; Auyeung, M.; Ostrem, J.L.; Visser-Vandewalle, V.; Welter, M-L.; Mallet, L.; Karachi, C.; Houeto, J.L.; Klassen, B.T.; Ackermans, L.; Kaido, T.; Temel, Y.; Gross, R.E.; Walker, H.C.; Lozano, A.M.; Walter, B.L.; Mari, Z.; Anderson, W.S.; Changizi, B.K.; Moro, E.; Zauber, S.E.; Schrock, L.E.; Zhang, J-G.; Hu, W.; Rizer, K.; Monari, E.H.; Foote, K.D.; Malaty, I.A.; Deeb, W.; Gunduz, A.; Okun, M.S. Efficacy and safety of deep brain stimulation in tourette syndrome. The international tourette syndrome deep brain stimulation public database and registry. JAMA Neurol., 2018, 75(3), 353-359. doi: 10.1001/jamaneurol.2017.4317
  33. Baldermann, J.C.; Kuhn, J.; Schüller, T.; Kohl, S.; Andrade, P.; Schleyken, S.; Prinz-Langenohl, R.; Hellmich, M.; Barbe, M.T.; Timmermann, L.; Visser-Vandewalle, V.; Huys, D. Thalamic deep brain stimulation for tourette syndrome: A naturalistic trial with brief randomized, double-blinded sham-controlled periods. Brain Stimul., 2021, 14(5), 1059-1067. doi: 10.1016/j.brs.2021.07.003
  34. Factor, S.A. Management of tardive syndrome: Medications and surgical treatments. Neurotherapeutics, 2020, 17(4), 1694-1712. doi: 10.1007/s13311-020-00898-3
  35. Szota, A.M.; Scheel-Krüger, J. The role of glutamate receptors and their interactions with dopamine and other neurotransmitters in the development of tardive dyskinesia: Preclinical and clinical results. Behav. Pharmacol., 2020, 31(6), 511-523. doi: 10.1097/FBP.0000000000000563
  36. Zutshi, D.; Cloud, L.J.; Factor, S.A. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: Experience from a university-based movement disorder clinic. Tremor Other Hyperkinet. Mov. , 2014, 4, 266. doi: 10.5334/tohm.199
  37. Pinninti, N.R.; Faden, J.; Adityanjee, A. Are second-generation antipsychotics useful in tardive dystonia? Clin. Neuropharmacol., 2015, 38(5), 183-197. doi: 10.1097/WNF.0000000000000106
  38. Mulroy, E.; Balint, B.; Bhatia, K.P. Tardive syndromes. Pract. Neurol., 2020, 20(5), 368-376. doi: 10.1136/practneurol-2020-002566
  39. Bhidayasiri, R.; Jitkritsadakul, O.; Friedman, J.H.; Fahn, S. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. J. Neurol. Sci., 2018, 389, 67-75. doi: 10.1016/j.jns.2018.02.010
  40. Mentzel, T; van der Snoek, R; Lieverse, R; Oorschot, M; Viechtbauer, W; Bloemen, O Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: A meta-analysis. J. Clin. Psychiatry, , 2018, 79(6), 17r11852 .
  41. Anderson, K.E.; Stamler, D.; Davis, M.D.; Factor, S.A.; Hauser, R.A.; Isojärvi, J.; Jarskog, L.F.; Jimenez-Shahed, J.; Kumar, R.; McEvoy, J.P.; Ochudlo, S.; Ondo, W.G.; Fernandez, H.H. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry, 2017, 4(8), 595-604. doi: 10.1016/S2215-0366(17)30236-5
  42. Fernandez, H.H.; Factor, S.A.; Hauser, R.A.; Jimenez-Shahed, J.; Ondo, W.G.; Jarskog, L.F.; Meltzer, H.Y.; Woods, S.W.; Bega, D.; LeDoux, M.S.; Shprecher, D.R.; Davis, C.; Davis, M.D.; Stamler, D.; Anderson, K.E. Randomized controlled trial of deutetrabenazine for tardive dyskinesia. Neurology, 2017, 88(21), 2003-2010. doi: 10.1212/WNL.0000000000003960
  43. Rascol, O.; Fabbri, M.; Poewe, W. Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol., 2021, 20(12), 1048-1056. doi: 10.1016/S1474-4422(21)00249-0
  44. Pappa, S.; Tsouli, S.; Apostolou, G.; Mavreas, V.; Konitsiotis, S. Effects of amantadine on tardive dyskinesia. Clin. Neuropharmacol., 2010, 33(6), 271-275. doi: 10.1097/WNF.0b013e3181ffde32
  45. Lin, C-C.; Ondo, W.G. Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. J. Neurol. Sci., 2018, 389, 48-54. doi: 10.1016/j.jns.2018.02.014
  46. Cornett, E.M.; Novitch, M.; Kaye, A.D.; Kata, V.; Kaye, A.M. Medication-induced tardive dyskinesia: A review and update. Ochsner J., 2017, 17(2), 162-174. PMID: 28638290
  47. Krause, P.; Kroneberg, D.; Gruber, D.; Koch, K.; Schneider, G.H.; Kühn, A.A. Long-term effects of pallidal deep brain stimulation in tardive dystonia: A follow-up of 5–14 years. J. Neurol., 2022, 269(7), 3563-3568. doi: 10.1007/s00415-022-10965-8
  48. Macerollo, A.; Deuschl, G. Deep brain stimulation for tardive syndromes: Systematic review and meta-analysis. J. Neurol. Sci., 2018, 389, 55-60. doi: 10.1016/j.jns.2018.02.013
  49. van den Heuvel, C.N.A.M.; Tijssen, M.A.J.; van de Warrenburg, B.P.C.; Delnooz, C.C.S. The symptomatic treatment of acquired dystonia: A systematic review. Mov. Disord. Clin. Pract., 2016, 3(6), 548-558. doi: 10.1002/mdc3.12400
  50. Gruber, D.; Südmeyer, M.; Deuschl, G.; Falk, D.; Krauss, J.K.; Mueller, J. Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial. Brain Stimulation; Elsevier Inc., 2018, 11, 1368-1377.
  51. Stahl, S.M. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects. CNS Spectr., 2018, 23(1), 1-6. doi: 10.1017/S1092852917000621
  52. Claassen, D.O.; Carroll, B.; De Boer, L.M.; Wu, E.; Ayyagari, R.; Gandhi, S.; Stamler, D. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J. Clin. Mov. Disord., 2017, 4(1), 3. doi: 10.1186/s40734-017-0051-5
  53. Mehanna, R.; Hunter, C.; Davidson, A.; Jimenez-Shahed, J.; Jankovic, J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov. Disord., 2013, 28(2), 210-215. doi: 10.1002/mds.25278
  54. Prestwick Pharmaceuticals, Inc. 2008. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf (cited: 7th of November 2022)
  55. Teva Pharmaceuticals, USA, Inc. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209885lbl.pdf (cited: 7th of November 2022).
  56. Neurocrine Biosciences, Inc. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf (cited: 7th of November 2022).
  57. Jankovic, J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin. Pharmacother., 2016, 17(18), 2461-2470. doi: 10.1080/14656566.2016.1258063
  58. Kaur, N.; Kumar, P.; Jamwal, S.; Deshmukh, R.; Gauttam, V. Tetrabenazine: Spotlight on drug review. Ann. Neurosci., 2016, 23(3), 176-185.
  59. Wisidagama, S.; Selladurai, A.; Wu, P.; Isetta, M.; Serra-Mestres, J. Recognition and management of antipsychotic-induced parkinsonism in older adults: A narrative review. Medicines , 2021, 8(6), 24. doi: 10.3390/medicines8060024
  60. Blanchet, K. Drug-induced parkinsonism: diagnosis and management. J. Parkinson. Restl. Leg. Syndr., 2016 2016. Available from: www.dovepress.com
  61. Bashir, H.; Jankovic, J. Treatment options for chorea.Exp. Rev. Neurotherap; Taylor and Francis Ltd, 2018, 18, 51-63. doi: 10.1080/14737175.2018.1403899
  62. Preskorn, S.H.; Fahnestock, P.A.; Carpenter, D.; Ross, R.; Docherty, J.P.; Alexopoulos, S. The roadmap for antipsychotic psychopharmacology: An overview. J. Clin. Psychiatry, 2007, 68.
  63. Gardner, D.M.; Baldessarini, R.J.; Waraich, P. Modern antipsychotic drugs: A critical overview. Canad. Med. Assoc. J., 2005, 172, 1703-1711.
  64. Waln, O.; Jankovic, J.; Cambridge, H.; Arnold, W.; Wilkins, W.B. An update on tardive dyskinesia: From phenomenology to treatment. Tremor Other Hyperkinet. Mov., 2013, 3, 03. doi: 10.5334/tohm.165
  65. Aguilar-Henriquez, A.; Mbbs, T.T.; Andrés, A.H.; Luba, L.; James, M. Psychotropic idiosyncratic drug reactions: A brief review of proposed mechanisms; In:; Int. J. Psychiatr. Res, 2019, p. 2.
  66. Strawn, J.R.; Keck, P.E.; Caroff, S.N. Treatment in psychiatry neuroleptic malignant syndrome scope and nature of neuroleptic malignant syndrome. Am. J. Psychiatry, 2007, 164.
  67. Jankovic, J. Medical treatment of dystonia. Mov. Disord., 2013, 28(7), 1001-1012. doi: 10.1002/mds.25552
  68. Wong, J.; Delva, N. Clozapine-induced seizures: Recognition and treatment. Can. J. Psychiatry, 2007, 52(7), 457-463. doi: 10.1177/070674370705200708
  69. Osborne, I.J.; McIvor, R.J. Clozapine-induced myoclonus: A case report and review of the literature. Ther. Adv. Psychopharmacol., 2015, 5(6), 351-356. doi: 10.1177/2045125315612015
  70. Hampe, C.S.; Mitoma, H.; Manto, M. GABA and Glutamate: Their transmitter role in the CNS and pancreatic islets.In: GABA And Glutamate - New Developments In Neurotransmission Research; InTech, , 2018.
  71. Excitatory, H.; John, M.S.; Adron, H.R. GABA and the GABAa receptor. J. Neurochem., 1997, 21, 1-27-131.
  72. Soyka, M. Treatment of benzodiazepine dependence. N. Engl. J. Med., 2017, 376(12), 1147-1157. doi: 10.1056/NEJMra1611832
  73. de las Cuevas, C.; Sanz, E.; de la Fuente, J. Benzodiazepines: More "behavioural" addiction than dependence. Psychopharmacology , 2003, 167(3), 297-303. doi: 10.1007/s00213-002-1376-8
  74. Gracies, J.M.; Nance, P.; Elovic, E.; McGuire, J.; Simpson, D.M. Traditional pharmacological treatments for spasticity part II: General and regional treatments. Muscle Nerve, 1997, 20(S6), 92-120. doi: 10.1002/(SICI)1097-4598(1997)6+3.0.CO;2-E
  75. Jinnah, H.A.; Factor, S.A. Diagnosis and treatment of dystonia. Neurol. Clin., 2015, 33(1), 77-100. doi: 10.1016/j.ncl.2014.09.002
  76. Holm, K.J.; Goa, K.L.; Cluydts, R. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs, 2000, 59(4), 865-889.
  77. Huang, M.C.; Lin, H.Y.; Chen, C.H. Dependence on zolpidem. Psychiatry Clin. Neurosci., 2007, 61(2), 207-208. doi: 10.1111/j.1440-1819.2007.01644.x
  78. Romito, J.W.; Turner, E.R.; Rosener, J.A.; Coldiron, L.; Udipi, A.; Nohrn, L.; Tausiani, J.; Romito, B.T. Baclofen therapeutics, toxicity, and withdrawal: A narrative review. SAGE Open Med., 2021, 9. doi: 10.1177/20503121211022197
  79. Caulfield, MP. Birdsall, NJM International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev., 1998, 50(2), 279-290.
  80. Kruse, A.C.; Kobilka, B.K.; Gautam, D.; Sexton, P.M.; Christopoulos, A.; Wess, J. Muscarinic acetylcholine receptors: Novel opportunities for drug development. Nat. Rev. Drug Discov. Nature Publishing Group, 2014, 13, 549-560.
  81. Miller, C.A. Anticholinergics: The good and the bad. Geriatr. Nurs., 2002, 23(5), 286-287. doi: 10.1067/mgn.2002.128791
  82. Downs, A.M.; Fan, X.; Donsante, C.; Jinnah, H.A.; Hess, E.J. Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia. Neurobiol. Dis., 2019, 125, 115-122. doi: 10.1016/j.nbd.2019.01.012
  83. Galarraga, E.; Herná Ndez-Ló Pez, S.; Reyes, A.; Miranda, I.; Bermudez-Rattoni, F.; Vilchis, C. Cholinergic modulation of neostriatal output: A functional antagonism between different types of muscarinic receptors. J. Neurosci., 1999, 19(9), 3629-3638. doi: 10.1523/JNEUROSCI.19-09-03629.1999
  84. Bergman, H.; Soares-Weiser, K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst. Rev., 2018, 1(1), CD000204. doi: 10.1002/14651858.CD000204.pub2
  85. Artukoglu, B.B.; Li, F.; Szejko, N.; Bloch, M.H. Pharmacologic treatment of tardive dyskinesia: A meta-analysis and systematic review. J. Clin. Psychiatry., 2020, 81(4), 19r12798. doi: 10.4088/JCP.19r12798
  86. Stroup, T.S.; Gray, N. Management of common adverse effects of antipsychotic medications. World Psychiatry, 2018, 17(3), 341-356. doi: 10.1002/wps.20567
  87. López-Álvarez, J.; Sevilla-Llewellyn-Jones, J.; Agüera-Ortiz, L. Anticholinergic drugs in geriatric psychopharmacology. Front. Neurosci., 2019, 13, 1309.
  88. Zhou, Y.; Danbolt, N.C. Glutamate as a neurotransmitter in the healthy brain. J. Neural Transm., 2014, 121(8), 799-817. doi: 10.1007/s00702-014-1180-8
  89. Sanacora, G.; Zarate, C.A.; Krystal, J.H.; Manji, H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov., 2008, 7(5), 426-437. doi: 10.1038/nrd2462
  90. Meldrum, BS. Glutamate and glutamine in the brain glutamate as a neurotransmitter in the brain: Review of physiology and pathology. J. Nutr., 2000, 130(4S), 1007S-1015S.
  91. Rascol, O.; Fabbri, M.; Poewe, W. Amantadine in the treatment of Parkinson’s disease and other movement disorders.The Lancet Neurology; Elsevier, 2021, 20, 1048-1056.
  92. Dragašević-Mišković, N.; Petrović, I.; Stanković, I.; Kostić, V.S. Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opinion on Pharmacotherapy; Taylor and Francis Ltd,, 2019, 20, 219-230.
  93. Caroff, S.N.; Jr, MJ.F. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann. Clin. Psychiatry, 2020, 32(3), 198-208.
  94. Kubo, S.; Iwatake, A.; Ebihara, N.; Murakami, A.; Hattori, N. Visual impairment in Parkinson’s disease treated with amantadine: Case report and review of the literature. Parkinsonism Relat. Disord., 2008, 14(2), 166-169. doi: 10.1016/j.parkreldis.2007.03.003
  95. Chang, C.; Ramphul, K. In: StatPearls; StatPearls Publishing, 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499953/ (cited: 14th November 2022).
  96. Siniscalchi, A.; Gallelli, L.; De Sarro, G. Use of antiepileptic drugs for hyperkinetic movement disorders. Curr. Neuropharmacol., 2010, 8(4), 359-366. doi: 10.2174/157015910793358187
  97. Bialer, M.; White, H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov., 2010, 9(1), 68-82. doi: 10.1038/nrd2997
  98. Yu, L.; Yan, J.; Wen, F.; Wang, F.; Liu, J.; Cui, Y.; Li, Y. Revisiting the efficacy and tolerability of topiramate for tic disorders: A meta-analysis. J. Child Adolesc. Psychopharmacol., 2020, 30(5), 316-325. doi: 10.1089/cap.2019.0161
  99. Walia, K.S.; Khan, E.A.; Ko, D.H.; Raza, S.S.; Khan, Y.N. Side effects of antiepileptics: A review. Pain Pract., 2004, 4(3), 194-203. doi: 10.1111/j.1533-2500.2004.04304.x
  100. Mutanana, N.; Tsvere, M.; Chiweshe, M.K. General side effects and challenges associated with anti-epilepsy medication: A review of related literature. Afr. J. Prim. Health Care Fam. Med., 2020, 12(1), e1-e5. doi: 10.4102/phcfm.v12i1.2162
  101. Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S. Botulinum toxin as a biological weapon medical and public health management. JAMA, 2001, 285(8), 1059-1070.
  102. Dressler, D.; Adib Saberi, F. Botulinum toxin: Mechanisms of action. Eur. Neurol., 2005, 53(1), 3-9. doi: 10.1159/000083259
  103. Marsh, W.A.; Monroe, D.M.; Brin, M.F.; Gallagher, C.J. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol., 2014, 14(1), 91. doi: 10.1186/1471-2377-14-91
  104. Anandan, C.; Jankovic, J. Botulinum toxin in movement disorders: An update. Toxins , 2021, 13(1), 42. doi: 10.3390/toxins13010042
  105. Kassir, M.; Gupta, M.; Galadari, H.; Kroumpouzos, G.; Katsambas, A.; Lotti, T. Complications of botulinum toxin and fillers: A narrative review. J. Cosmet. Dermatol., 2020, 19(3), 570-573. doi: 10.1111/jocd.13266
  106. Kroumpouzos, G.; Kassir, M.; Gupta, M.; Patil, A.; Goldust, M. Complications of Botulinum toxin A: An update review. J. Cosmet. Dermatol., 2021, 20, 1585-15920.
  107. Witmanowski, H.; Błochowiak, K. The whole truth about botulinum toxin: A review. Postepy Dermatologii i Alergologii. Termedia Publishing House Ltd, 2021, 37, 853-861.
  108. Jinnah, H.A. Medical and surgical treatments for dystonia. Neurol. Clin., 2020, 38(2), 325-348. doi: 10.1016/j.ncl.2020.01.003
  109. George, E.; Shneyder, N. Reduction in post-botulinum toxin flu-like symptoms after injection with incobotulinum toxin. Neurology, 2014, 2014(08), 82.
  110. Baizabal-Carvallo, J.F.; Jankovic, J.; Pappert, E. Flu-like symptoms following botulinum toxin therapy. Toxicon, 2011, 58(1), 1-7. doi: 10.1016/j.toxicon.2011.04.019
  111. Albrecht, P.; Jansen, A.; Lee, J.I.; Moll, M.; Ringelstein, M.; Rosenthal, D.; Bigalke, H.; Aktas, O.; Hartung, H-P.; Hefter, H. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology, 2019, 92(1), e48-e54. doi: 10.1212/WNL.0000000000006688
  112. Ho, W.W.S.; Albrecht, P.; Calderon, P.E.; Corduff, N.; Loh, D.; Martin, M.U.; Park, J-Y.; Suseno, L.S.; Tseng, F-W.; Vachiramon, V.; Wanitphakdeedecha, R.; Won, C-H.; Yu, J.N.T.; Dingley, M. Emerging trends in botulinum neurotoxin a resistance: An international multidisciplinary review and consensus. Plast. Reconstr. Surg. Glob. Open, 2022, 10(6), e4407. doi: 10.1097/GOX.0000000000004407
  113. Farr, S.T. Resistance to botulinum toxins in aesthetics. Botulinum Toxins and Botulism; Nova Science Publishers, Inc., 2015, pp. 1-15.
  114. Ashkan, K.; Rogers, P.; Bergman, H.; Ughratdar, I. Insights into the mechanisms of deep brain stimulation. Nat. Rev. Neurol. Nature Publishing Group, 2017, 13, 548-554.
  115. Chan, D.T.M.; Zhu, X.L.; Yeung, J.H.M.; Mok, V.C.T.; Wong, E.; Lau, C. Complications of deep brain stimulation: A collective review. Asian J. Surgery. Elsevier. Pte Ltd: Singapore, 2009, 32, 258-263.
  116. Patel, D.M.; Walker, H.C.; Brooks, R.; Omar, N.; Ditty, B.; Guthrie, B.L. Adverse events associated with deep brain stimulation for movement disorders: Analysis of 510 consecutive cases. Oper. Neurosurg. , 2015, 11(1), 190-199. doi: 10.1227/NEU.0000000000000659
  117. Jung, I.H.; Chang, K.W.; Park, S.H.; Chang, W.S.; Jung, H.H.; Chang, J.W. Complications after deep brain stimulation: A 21-year experience in 426 patients. Front. Aging Neurosci., 2022, 14, 819730. doi: 10.3389/fnagi.2022.819730
  118. Zarzycki, M.Z.; Domitrz, I. Stimulation-induced side effects after deep brain stimulation: A systematic review. Acta Neuropsychiatrica; Cambridge University Press,; , 2020, 32, pp. 57-64.
  119. Strotzer, Q.D.; Kohl, Z.; Anthofer, J.M.; Faltermeier, R.; Schmidt, N.O.; Torka, E.; Greenlee, M.W.; Fellner, C.; Schlaier, J.R.; Beer, A.L. Structural connectivity patterns of side effects induced by subthalamic deep brain stimulation for Parkinson’s disease. Brain Connect., 2022, 12(4), 374-384. doi: 10.1089/brain.2021.0051
  120. Reese, R.; Volkmann, J. Deep brain stimulation for the dystonias: Evidence, knowledge gaps, and practical considerations. Movement Disorders Clinical Practice; Wiley-Blackwell, 2017, 4, 486-494.
  121. Zarzycki, M.Z.; Domitrz, I. Stimulation-induced side effects after deep brain stimulation: A systematic review. . Acta Neuropsychiatrica; Cambridge University Press, ; , 2020, 32, pp. 57-64.
  122. Au, K.L.K.; Wong, J.K.; Tsuboi, T.; Eisinger, R.S.; Moore, K.; Lemos Melo Lobo Jofili Lopes, J.; Holland, M.T.; Holanda, V.M.; Peng-Chen, Z.; Patterson, A.; Foote, K.D.; Ramirez-Zamora, A.; Okun, M.S.; Almeida, L. Globus pallidus internus (GPi) deep brain stimulation for Parkinson’s disease: Expert review and commentary. Neurol. Ther., 2021, 10(1), 7-30. doi: 10.1007/s40120-020-00220-5
  123. Buhmann, C.; Huckhagel, T.; Engel, K.; Gulberti, A.; Hidding, U.; Poetter-Nerger, M.; Goerendt, I.; Ludewig, P.; Braass, H.; Choe, C.; Krajewski, K.; Oehlwein, C.; Mittmann, K.; Engel, A.K.; Gerloff, C.; Westphal, M.; Köppen, J.A.; Moll, C.K.E.; Hamel, W. Adverse events in deep brain stimulation: A retrospective long-term analysis of neurological, psychiatric and other occurrences. PLoS One, 2017, 12(7), e0178984. doi: 10.1371/journal.pone.0178984
  124. An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia (AUDYT). 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04173260 (Cited: 21st December 2022).
  125. Bledsoe, I.O.; Viser, A.C.; San Luciano, M. Treatment of dystonia: Medications, neurotoxins, neuromodulation, and rehabilitation. Neurotherapeutics, 2020, 17(4), 1622-1644. doi: 10.1007/s13311-020-00944-0
  126. Solish, N.; Carruthers, J.; Kaufman, J.; Rubio, R.G.; Gross, T.M.; Gallagher, C.J. Overview of daxibotulinumtoxina for injection: A novel formulation of botulinum toxin type A. Drugs, 2021, 81(18), 2091-2101. doi: 10.1007/s40265-021-01631-w
  127. Berweck, S.; Feldkamp, A.; Francke, A.; Nehles, J.; Schwerin, A.; Heinen, F. Sonography-guided injection of botulinum toxin a in children with cerebral palsy. Neuropediatrics, 2002, 33(4), 221-223. doi: 10.1055/s-2002-34500
  128. Chen, HWW. Ultrasound-guided botulinum toxin injections and EMG biofeedback therapy the lower limb muscle spasm after cerebral infarction. Eur. Rev. Med. Pharmacol. Sci., 2015, 19(9), 1696-1699.
  129. Sung, D.H.; Choi, J.Y.; Kim, D.H.; Kim, E.S.; Son, Y.I.; Cho, Y.S.; Lee, S.J.; Lee, K-H.; Kim, B-T. Localization of dystonic muscles with 18F-FDG PET/CT in idiopathic cervical dystonia. J. Nucl. Med., 2007, 48(11), 1790-1795. doi: 10.2967/jnumed.107.044024
  130. Krauss, J.K.; Lipsman, N.; Aziz, T.; Boutet, A.; Brown, P.; Chang, J.W. Technology of deep brain stimulation: Current status and future directions. Nat. Rev. Neurol., 2021, 17, 75-87.
  131. Horisawa, S.; Yamaguchi, T.; Abe, K.; Hori, H.; Sumi, M.; Konishi, Y.; Taira, T. A single case of MRI-guided focused ultrasound ventro-oral thalamotomy for musician’s dystonia. J. Neurosurg., 2019, 131(2), 384-386. doi: 10.3171/2018.5.JNS173125
  132. Fasano, A.; Llinas, M.; Munhoz, R.P.; Hlasny, E.; Walter Kucharczyk, M. Lozano, AM MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes. Neurology, 2017, 89(8), 771-775. doi: 10.1212/WNL.0000000000004268

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024